TD Cowen began coverage of Nektar Therapeutics on July 2, 2026, coinciding with an insider selling 5,538 shares of the company's stock.
1 report, 1 independent
Updated Jul 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen began coverage of Nektar Therapeutics on July 2, 2026, coinciding with an insider selling 5,538 shares of the company's stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Nektar Therapeutics
American healthcare company
Nothing else this week.
Related events
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
- Multiple financial firms, including KBC Group NV, WINTON GROUP Ltd, and Deutsche Bank, increased their stakes in Nektar Therapeutics on September 12, 2026.
- Jefferies and TD Cowen started research coverage for Acadia Healthcare on September 3, 2026.
- TD Cowen lowered its price target for Navan, Inc. stock on September 10, 2026.
- TD Cowen provided analyst ratings and price targets for Ardelyx, accompanied by required stock transaction filings with the SEC.